At Manningham Medical Centre, you can find all the data about Hansa Medical Ides. We have collected data about general practitioners, medical and surgical specialists, dental, pharmacy and more. Please see the links below for the information you need.


Hansa Medical receives FDA Orphan Drug Designation …

    https://www.gbs-cidp.org/2018/02/hansa-medical-receives-fda-orphan-drug-designation-ides-treatment-guillain-barre-syndrome/
    Hansa Medical today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation (ODD) to IdeS (INN: Imlifidase) for the treatment of Guillain-Barré syndrome (GBS). Hansa Medical, a Swedish company, is developing a drug, IdeS, which inactivates IgG. This inactivation would be like an instant plasmapheresis treatment.

Hansa Medical receives FDA Orphan Drug Designation for IdeS

    https://www.hansabiopharma.com/media/press-releases/2015/hansa-medical-receives-fda-orphan-drug-designation-for-ides/
    Hansa Medical today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation (ODD) to IdeS for the prevention of antibody mediated …

Ides in Highly Sensitized (HS) Patients Awaiting Kidney …

    https://clinicaltrials.gov/ct2/show/NCT02426684
    This is a single center phase I/II open label, exploratory study assessing safety and efficacy of IdeS® (Hansa Medical, Lund, Sweden) given immediately prior to …

Hansa Biopharma

    https://www.hansabiopharma.com/
    At Hansa, we are focused on the bigger picture and want help rare disease patients live long and healthy lives. We do this also by constant engagement with the …

Hansa Medical: Successful Desensitization with IdeS in …

    https://www.businesswire.com/news/home/20160614006528/en/Hansa-Medical-Successful-Desensitization-with-IdeS-in-All-Recruited-Patients-in-Ongoing-US-Phase-II-Study
    Hansa Medical is a biopharmaceutical company focusing on novel immunomodulatory enzymes. The lead project IdeS is an antibody-degrading enzyme in …

Our technology platform | Hansa Biopharma

    https://www.hansabiopharma.com/our-technology-platform/
    This is Hansa. This is Hansa. Vision, mission and strategy; Our leadership; Corporate governance. Governance committees; General meeting; Remuneration policy; …

Hansa Medical receives FDA Orphan Drug Designation …

    https://www.globenewswire.com/en/news-release/2015/09/14/768014/0/en/Hansa-Medical-receives-FDA-Orphan-Drug-Designation-for-IdeS.html
    Hansa Medical currently conducts Phase II trials with candidate drug IdeS for the prevention of antibody mediated organ rejection in kidney transplant patients.

Hansa Medical Year-End Report 2016 | Hansa Biopharma

    https://www.hansabiopharma.com/media/press-releases/2017/hansa-medical-year-end-report-2016/
    Hansa Medical acquired UK-based biotech company Immago Biosystems Ltd to investigate cancer immunotherapy applications with IdeS and EndoS Promising initial results from …

Stock information | Hansa Biopharma

    https://www.hansabiopharma.com/investors/stock-information/
    Stock Chart. 1 month. OMX Stockholm PI. 100 90 80 70 60 50. 40. SEK. Volume, thousands. 13 19 26 3 10 17 24 31 1 7 14 21 28 1 4 11. June July August September.

Complete Removal of Extracellular IgG Antibodies in a

    https://pubmed.ncbi.nlm.nih.gov/26177518/
    IdeS is a streptococcal protease that cleaves IgG antibodies into F(ab’)2 and Fc fragments with a unique degree of specificity, thereby providing a novel treatment …



Need more information about Hansa Medical Ides?

At Manningham Medical Centre, we collected data on more than just Hansa Medical Ides. There is a lot of other useful information. Visit the related pages or our most popular pages. Also check out our Doctors page.